Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double-Blind Placebo-Controlled Study of DCR-PHXC in Primary Hyperoxaluria
2018-003098-91Phase 2Completed
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Dec 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary hyperoxaluria (PH) and hyperoxaluria comparing DCR-PHXC with Placebo (2 arms). Started Dec 2018; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)hyperoxaluria
Beyond the preview
Go deeper on 2018-003098-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003098-91.